Does the media favor DFTX or HROW?

In the previous week, Definium Therapeutics had 3 more articles in the media than Harrow. MarketBeat recorded 9 mentions for Definium Therapeutics and 6 mentions for Harrow. Harrow's average media sentiment score of 0.71 beat Definium Therapeutics' score of 0.62 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MANE or HROW more profitable?

Veradermics has a net margin of 0.00% compared to Harrow's net margin of -13.51%. Veradermics' return on equity of 0.00% beat Harrow's return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Harrow -13.51% -38.00% -3.37%

Does the media refer more to MANE or HROW?

In the previous week, Veradermics had 3 more articles in the media than Harrow. MarketBeat recorded 9 mentions for Veradermics and 6 mentions for Harrow. Harrow's average media sentiment score of 0.71 beat Veradermics' score of 0.31 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, HROW or INDV?

Indivior has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $272.30M 5.64 -$5.14M -$1.00 N/A Indivior $1.24B 3.51 $210M $2.79 13.22

Is HROW or INDV more profitable?

Indivior has a net margin of 26.65% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -13.51% -38.00% -3.37% Indivior 26.65% -283.11% 36.85%

Does the media refer more to HROW or INDV?

In the previous week, Harrow had 4 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Harrow and 2 mentions for Indivior. Harrow's average media sentiment score of 0.71 beat Indivior's score of 0.52 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Harrow (HROW) Competitors

$40.95 -1.11 (-2.64%)

As of 08/21/2026 04:00 PM Eastern

Compare

HROW vs. AMRX, DFTX, MANE, INDV, and CPRX

Should you buy Harrow stock or one of its competitors? Harrow's main competitors and comparable companies include Amneal Pharmaceuticals (AMRX), Definium Therapeutics (DFTX), Veradermics (MANE), Indivior (INDV), and Catalyst Pharmaceuticals (CPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Harrow compare to Amneal Pharmaceuticals?

Harrow (NASDAQ:HROW) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Harrow has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.64	-$5.14M	-$1.00	N/A
Amneal Pharmaceuticals	$3.12B	1.83	$72.06M	$0.49	36.55

In the previous week, Harrow had 6 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 6 mentions for Harrow and 0 mentions for Amneal Pharmaceuticals. Harrow's average media sentiment score of 0.71 beat Amneal Pharmaceuticals' score of 0.00 indicating that Harrow is being referred to more favorably in the media.

Company	Overall Sentiment
Harrow	Positive
Amneal Pharmaceuticals	Neutral

72.8% of Harrow shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Harrow currently has a consensus target price of $69.43, indicating a potential upside of 69.54%. Amneal Pharmaceuticals has a consensus target price of $17.67, indicating a potential downside of 1.36%. Given Harrow's higher probable upside, equities research analysts clearly believe Harrow is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Amneal Pharmaceuticals beats Harrow on 10 of the 17 factors compared between the two stocks.

How does Harrow compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Harrow (NASDAQ:HROW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Definium Therapeutics presently has a consensus price target of $63.00, indicating a potential upside of 40.28%. Harrow has a consensus price target of $69.43, indicating a potential upside of 69.54%. Given Harrow's higher probable upside, analysts plainly believe Harrow is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harrow	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Definium Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, Harrow has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

In the previous week, Definium Therapeutics had 3 more articles in the media than Harrow. MarketBeat recorded 9 mentions for Definium Therapeutics and 6 mentions for Harrow. Harrow's average media sentiment score of 0.71 beat Definium Therapeutics' score of 0.62 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Definium Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Harrow	-13.51%	-38.00%	-3.37%

Harrow has higher revenue and earnings than Definium Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Harrow	$272.30M	5.64	-$5.14M	-$1.00	N/A

Summary

Harrow beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Harrow compare to Veradermics?

Veradermics (NYSE:MANE) and Harrow (NASDAQ:HROW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Harrow has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Harrow, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Harrow	$272.30M	5.64	-$5.14M	-$1.00	N/A

In the previous week, Veradermics had 3 more articles in the media than Harrow. MarketBeat recorded 9 mentions for Veradermics and 6 mentions for Harrow. Harrow's average media sentiment score of 0.71 beat Veradermics' score of 0.31 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Veradermics has a net margin of 0.00% compared to Harrow's net margin of -13.51%. Veradermics' return on equity of 0.00% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Harrow	-13.51%	-38.00%	-3.37%

Veradermics currently has a consensus target price of $153.00, indicating a potential upside of 48.07%. Harrow has a consensus target price of $69.43, indicating a potential upside of 69.54%. Given Harrow's higher probable upside, analysts clearly believe Harrow is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Harrow	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Harrow beats Veradermics on 9 of the 14 factors compared between the two stocks.

How does Harrow compare to Indivior?

Harrow (NASDAQ:HROW) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Indivior has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.64	-$5.14M	-$1.00	N/A
Indivior	$1.24B	3.51	$210M	$2.79	13.22

In the previous week, Harrow had 4 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Harrow and 2 mentions for Indivior. Harrow's average media sentiment score of 0.71 beat Indivior's score of 0.52 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow presently has a consensus target price of $69.43, indicating a potential upside of 69.54%. Indivior has a consensus target price of $45.17, indicating a potential upside of 22.50%. Given Harrow's higher probable upside, research analysts clearly believe Harrow is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Harrow has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

72.8% of Harrow shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Indivior has a net margin of 26.65% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Indivior	26.65%	-283.11%	36.85%

Summary

Harrow and Indivior tied by winning 8 of the 16 factors compared between the two stocks.

How does Harrow compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Harrow (NASDAQ:HROW) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Harrow's net margin of -13.51%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Harrow	-13.51%	-38.00%	-3.37%

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Harrow has a consensus target price of $69.43, suggesting a potential upside of 69.54%. Given Harrow's higher probable upside, analysts plainly believe Harrow is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Harrow	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, Harrow had 6 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Harrow and 0 mentions for Catalyst Pharmaceuticals. Harrow's average media sentiment score of 0.71 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Harrow is being referred to more favorably in the news media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Neutral
Harrow	Positive

Catalyst Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Harrow has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10
Harrow	$272.30M	5.64	-$5.14M	-$1.00	N/A

Summary

Catalyst Pharmaceuticals beats Harrow on 12 of the 17 factors compared between the two stocks.

Get Harrow News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HROW vs. The Competition

Export

Metric	Harrow	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.54B	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	-40.95	789.80	272.60	24.24
Price / Sales	5.64	764.50	618.96	99.81
Price / Cash	47.38	96.77	78.62	53.99
Price / Book	102.38	11.89	13.05	6.20
Net Income	-$5.14M	$2.81B	$3.47B	$348.59M
7 Day Performance	2.30%	1.77%	2.09%	0.08%
1 Month Performance	-2.22%	3.85%	6.64%	3.88%
1 Year Performance	4.68%	6.56%	25.02%	16.98%

Harrow Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HROW Harrow	2.3993 of 5 stars	$40.95 -2.6%	$69.43 +69.5%	+4.7%	$1.54B	$272.30M	N/A	180
AMRX Amneal Pharmaceuticals	2.4074 of 5 stars	$18.42 +1.5%	$17.67 -4.1%	+86.8%	$5.80B	$3.02B	37.59	8,500
DFTX Definium Therapeutics	3.1165 of 5 stars	$45.26 +6.2%	$62.14 +37.3%	+340.7%	$5.73B	N/A	N/A	40	Analyst Forecast Options Volume
MANE Veradermics	2.2372 of 5 stars	$107.76 -4.4%	$153.00 +42.0%	N/A	$4.71B	N/A	N/A	19	News Coverage Insider Trade
INDV Indivior	3.8896 of 5 stars	$39.08 +0.2%	$45.17 +15.6%	+51.6%	$4.60B	$1.24B	14.01	1,051	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HROW) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harrow (HROW) Competitors

HROW vs. AMRX, DFTX, MANE, INDV, and CPRX

How does Harrow compare to Amneal Pharmaceuticals?

Summary

How does Harrow compare to Definium Therapeutics?

Summary

How does Harrow compare to Veradermics?

Summary

How does Harrow compare to Indivior?

Summary

How does Harrow compare to Catalyst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW vs. The Competition

Harrow Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harrow (HROW) Competitors

HROW vs. AMRX, DFTX, MANE, INDV, and CPRX

How does Harrow compare to Amneal Pharmaceuticals?

Is HROW or AMRX more profitable?

Which has more risk and volatility, HROW or AMRX?

Which has better earnings and valuation, HROW or AMRX?

Does the media prefer HROW or AMRX?

Do institutionals & insiders believe in HROW or AMRX?

Do analysts rate HROW or AMRX?

Summary

How does Harrow compare to Definium Therapeutics?

Do analysts rate DFTX or HROW?

Which has more risk and volatility, DFTX or HROW?

Does the media favor DFTX or HROW?

Do institutionals & insiders believe in DFTX or HROW?

Is DFTX or HROW more profitable?

Which has stronger valuation & earnings, DFTX or HROW?

Summary

How does Harrow compare to Veradermics?

Which has better earnings and valuation, MANE or HROW?

Does the media refer more to MANE or HROW?

Do institutionals and insiders believe in MANE or HROW?

Is MANE or HROW more profitable?

Do analysts rate MANE or HROW?

Summary

How does Harrow compare to Indivior?

Which has stronger valuation and earnings, HROW or INDV?

Does the media refer more to HROW or INDV?

Do analysts prefer HROW or INDV?

Which has more risk & volatility, HROW or INDV?

Do insiders & institutionals have more ownership in HROW or INDV?

Is HROW or INDV more profitable?

Summary

How does Harrow compare to Catalyst Pharmaceuticals?

Do insiders and institutionals hold more shares of CPRX or HROW?

Is CPRX or HROW more profitable?

Do analysts prefer CPRX or HROW?

Does the media favor CPRX or HROW?

Which has more risk and volatility, CPRX or HROW?

Which has stronger earnings and valuation, CPRX or HROW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW vs. The Competition

Harrow Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools